Direkt zum Inhalt
Merck
  • Long-term sustained release of salicylic acid from cross-linked biodegradable polyester induces a reduced foreign body response in mice.

Long-term sustained release of salicylic acid from cross-linked biodegradable polyester induces a reduced foreign body response in mice.

Biomacromolecules (2015-01-07)
Yashoda Chandorkar, Nitu Bhaskar, Giridhar Madras, Bikramjit Basu
ZUSAMMENFASSUNG

There has been a continuous surge toward developing new biopolymers that exhibit better in vivo biocompatibility properties in terms of demonstrating a reduced foreign body response (FBR). One approach to mitigate the undesired FBR is to develop an implant capable of releasing anti-inflammatory molecules in a sustained manner over a long time period. Implants causing inflammation are also more susceptible to infection. In this article, the in vivo biocompatibility of a novel, biodegradable salicylic acid releasing polyester (SAP) has been investigated by subcutaneous implantation in a mouse model. The tissue response to SAP was compared with that of a widely used biodegradable polymer, poly(lactic acid-co-glycolic acid) (PLGA), as a control over three time points: 2, 4, and 16 weeks postimplantation. A long-term in vitro study illustrates a continuous, linear (zero order) release of salicylic acid with a cumulative mass percent release rate of 7.34 × 10(-4) h(-1) over ∼1.5-17 months. On the basis of physicochemical analysis, surface erosion for SAP and bulk erosion for PLGA have been confirmed as their dominant degradation modes in vivo. On the basis of the histomorphometrical analysis of inflammatory cell densities and collagen distribution as well as quantification of proinflammatory cytokine levels (TNF-α and IL-1β), a reduced foreign body response toward SAP with respect to that generated by PLGA has been unambiguously established. The favorable in vivo tissue response to SAP, as manifest from the uniform and well-vascularized encapsulation around the implant, is consistent with the decrease in inflammatory cell density and increase in angiogenesis with time. The above observations, together with the demonstration of long-term and sustained release of salicylic acid, establish the potential use of SAP for applications in improved matrices for tissue engineering and chronic wound healing.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Pyridin, ACS reagent, ≥99.0%
Sigma-Aldrich
Pyridin, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Pyridin, anhydrous, 99.8%
Sigma-Aldrich
D-Mannitol, ≥98% (GC)
Sigma-Aldrich
Essigsäureanhydrid, ReagentPlus®, ≥99%
Sigma-Aldrich
Salicylsäure, ACS reagent, ≥99.0%
Sigma-Aldrich
Milchsäure, meets USP testing specifications
Sigma-Aldrich
Glycolsäure, ReagentPlus®, 99%
Supelco
D-Mannitol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-Mannitol, ACS reagent
Sigma-Aldrich
Milchsäure, 88%, FCC
Sigma-Aldrich
Essigsäureanhydrid, ACS reagent, ≥98.0%
Supelco
Salicylsäure, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-Mannitol, ≥98% (GC), suitable for plant cell culture
Sigma-Aldrich
Milchsäure, natural, ≥85%
Sigma-Aldrich
Essigsäureanhydrid, 99.5%
Sigma-Aldrich
Milchsäure -Lösung, ACS reagent, ≥85%
USP
Mannitol, United States Pharmacopeia (USP) Reference Standard
USP
Salicylsäure, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
DL-Milchsäure, ~90% (T)
Supelco
Milchsäure, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-Mannitol, BioUltra, ≥99.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
D-Mannitol, meets EP, FCC, USP testing specifications
Sigma-Aldrich
Sebacoylchlorid, 99%
Sigma-Aldrich
Salicylsäure, BioXtra, ≥99.0%
Sigma-Aldrich
Pyridin, ≥99%
Sigma-Aldrich
Salicylsäure, ≥99%, FG
Sigma-Aldrich
D-Mannitol, BioXtra, ≥98% (HPLC)
Mannitol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Glycolsäure -Lösung, technical grade, 70 wt. % in H2O